Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
37
PRLD Quote, Financials, Valuation and Earnings
Last price:
$1.45
Seasonality move
:
-0.12%
Day range:
$1.43 - $1.56
52-week range:
$0.61 - $4.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.85x
P/B ratio:
1.57x
Volume:
292.8K
Avg. volume:
2.6M
1-year change:
55.92%
Market cap:
$91.8M
Revenue:
$7M
EPS (TTM):
-$1.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
-- | -$0.36 | 412.5% | -65.45% | $4.00 |
|
ALXO
ALX Oncology Holdings, Inc.
|
-- | -$0.26 | -- | -42.06% | $3.00 |
|
ERAS
Erasca, Inc.
|
-- | -$0.11 | -- | -10.71% | $5.00 |
|
INCY
Incyte Corp.
|
$1.3B | $1.64 | 14.58% | 87.25% | $95.57 |
|
NAUT
Nautilus Biotechnology, Inc.
|
-- | -$0.15 | -- | -- | $2.50 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
$1.46 | $4.00 | $91.8M | -- | $0.00 | 0% | 9.85x |
|
ALXO
ALX Oncology Holdings, Inc.
|
$1.42 | $3.00 | $77M | -- | $0.00 | 0% | 8.93x |
|
ERAS
Erasca, Inc.
|
$3.27 | $5.00 | $927.7M | -- | $0.00 | 0% | -- |
|
INCY
Incyte Corp.
|
$102.52 | $95.57 | $20.1B | 17.20x | $0.00 | 0% | 4.24x |
|
NAUT
Nautilus Biotechnology, Inc.
|
$2.03 | $2.50 | $256.4M | -- | $0.00 | 0% | -- |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.73 | $11.00 | $139.1M | 24.89x | $0.00 | 0% | 2.20x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
23.37% | -0.451 | 21.91% | 3.02x |
|
ALXO
ALX Oncology Holdings, Inc.
|
25.84% | 3.782 | 15.92% | 2.19x |
|
ERAS
Erasca, Inc.
|
12.19% | 0.836 | 7.81% | 10.04x |
|
INCY
Incyte Corp.
|
0.88% | 1.735 | 0.25% | 2.86x |
|
NAUT
Nautilus Biotechnology, Inc.
|
13.77% | 4.123 | 25.3% | 14.63x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRLD
Prelude Therapeutics, Inc.
|
$6.1M | -$20.4M | -90.83% | -106.36% | -314.12% | -$19.1M |
|
ALXO
ALX Oncology Holdings, Inc.
|
-$153K | -$22.5M | -101.77% | -120.56% | -- | -$17.1M |
|
ERAS
Erasca, Inc.
|
-$755K | -$32.5M | -28.42% | -32.03% | -- | -$21.7M |
|
INCY
Incyte Corp.
|
$1.2B | $431.3M | 30.74% | 31.1% | 31.58% | $519.6M |
|
NAUT
Nautilus Biotechnology, Inc.
|
-$1.6M | -$15.5M | -27.96% | -32.15% | -- | -$11.5M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Prelude Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns PRLD or ALXO?
ALX Oncology Holdings, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of --. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat ALX Oncology Holdings, Inc.'s return on equity of -120.56%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M ALXOALX Oncology Holdings, Inc.-- -$0.41 $60.4M -
What do Analysts Say About PRLD or ALXO?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 173.97%. On the other hand ALX Oncology Holdings, Inc. has an analysts' consensus of $3.00 which suggests that it could grow by 111.27%. Given that Prelude Therapeutics, Inc. has higher upside potential than ALX Oncology Holdings, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than ALX Oncology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.1 0 0 ALXOALX Oncology Holdings, Inc.3 1 0 -
Is PRLD or ALXO More Risky?
Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison ALX Oncology Holdings, Inc. has a beta of 0.526, suggesting its less volatile than the S&P 500 by 47.364%.
-
Which is a Better Dividend Stock PRLD or ALXO?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ALX Oncology Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. ALX Oncology Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or ALXO?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are larger than ALX Oncology Holdings, Inc. quarterly revenues of --. Prelude Therapeutics, Inc.'s net income of -$19.7M is higher than ALX Oncology Holdings, Inc.'s net income of -$22.1M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while ALX Oncology Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 9.85x versus 8.93x for ALX Oncology Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.9.85x -- $6.5M -$19.7M ALXOALX Oncology Holdings, Inc.8.93x -- -- -$22.1M
-
Which has Higher Returns PRLD or ERAS?
Erasca, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of --. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Erasca, Inc.'s return on equity of -32.03%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M ERASErasca, Inc.-- -$0.11 $396.2M -
What do Analysts Say About PRLD or ERAS?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 173.97%. On the other hand Erasca, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 52.91%. Given that Prelude Therapeutics, Inc. has higher upside potential than Erasca, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Erasca, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.1 0 0 ERASErasca, Inc.6 1 0 -
Is PRLD or ERAS More Risky?
Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Erasca, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRLD or ERAS?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Erasca, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Erasca, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or ERAS?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are larger than Erasca, Inc. quarterly revenues of --. Prelude Therapeutics, Inc.'s net income of -$19.7M is higher than Erasca, Inc.'s net income of -$30.6M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Erasca, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 9.85x versus -- for Erasca, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.9.85x -- $6.5M -$19.7M ERASErasca, Inc.-- -- -- -$30.6M
-
Which has Higher Returns PRLD or INCY?
Incyte Corp. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of 31.05%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Incyte Corp.'s return on equity of 31.1%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M INCYIncyte Corp.91.5% $2.11 $4.7B -
What do Analysts Say About PRLD or INCY?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 173.97%. On the other hand Incyte Corp. has an analysts' consensus of $95.57 which suggests that it could fall by -6.78%. Given that Prelude Therapeutics, Inc. has higher upside potential than Incyte Corp., analysts believe Prelude Therapeutics, Inc. is more attractive than Incyte Corp..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.1 0 0 INCYIncyte Corp.9 12 2 -
Is PRLD or INCY More Risky?
Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.810, suggesting its less volatile than the S&P 500 by 18.956%.
-
Which is a Better Dividend Stock PRLD or INCY?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or INCY?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are smaller than Incyte Corp. quarterly revenues of $1.4B. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Incyte Corp.'s net income of $424.2M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Incyte Corp.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 9.85x versus 4.24x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.9.85x -- $6.5M -$19.7M INCYIncyte Corp.4.24x 17.20x $1.4B $424.2M
-
Which has Higher Returns PRLD or NAUT?
Nautilus Biotechnology, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of --. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Nautilus Biotechnology, Inc.'s return on equity of -32.15%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M NAUTNautilus Biotechnology, Inc.-- -$0.11 $196.1M -
What do Analysts Say About PRLD or NAUT?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 173.97%. On the other hand Nautilus Biotechnology, Inc. has an analysts' consensus of $2.50 which suggests that it could grow by 23.15%. Given that Prelude Therapeutics, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.1 0 0 NAUTNautilus Biotechnology, Inc.2 0 0 -
Is PRLD or NAUT More Risky?
Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Nautilus Biotechnology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRLD or NAUT?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nautilus Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Nautilus Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or NAUT?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are larger than Nautilus Biotechnology, Inc. quarterly revenues of --. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Nautilus Biotechnology, Inc.'s net income of -$13.6M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Nautilus Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 9.85x versus -- for Nautilus Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.9.85x -- $6.5M -$19.7M NAUTNautilus Biotechnology, Inc.-- -- -- -$13.6M
-
Which has Higher Returns PRLD or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -303.46% compared to Prelude Therapeutics, Inc.'s net margin of 13.19%. Prelude Therapeutics, Inc.'s return on equity of -106.36% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital PRLDPrelude Therapeutics, Inc.93.46% -$0.26 $76.4M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About PRLD or PLX?
Prelude Therapeutics, Inc. has a consensus price target of $4.00, signalling upside risk potential of 173.97%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Prelude Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Prelude Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRLDPrelude Therapeutics, Inc.1 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is PRLD or PLX More Risky?
Prelude Therapeutics, Inc. has a beta of 1.065, which suggesting that the stock is 6.517% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock PRLD or PLX?
Prelude Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prelude Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRLD or PLX?
Prelude Therapeutics, Inc. quarterly revenues are $6.5M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Prelude Therapeutics, Inc.'s net income of -$19.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Prelude Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prelude Therapeutics, Inc. is 9.85x versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRLDPrelude Therapeutics, Inc.9.85x -- $6.5M -$19.7M PLXProtalix Biotherapeutics, Inc.2.20x 24.89x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
